Recruiting
Phase 1,
Phase 2
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
ClinicalTrials.gov Identifier
Eligibility criteria
Sex
Age
18 Years - 65 Years
Phase
1, 2
Key inclusion criteria
- Clinical history of T1D with greater than or equal to (>=) 5 years duration
- Participant is on a stable diabetic treatment
- Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Key exclusion criteria
- Prior islet cell transplant, organ transplant, or cell therapy
Other protocol defined Inclusion/Exclusion criteria may apply.
Trial details
Condition
Type 1 Diabetes
Study duration
May 2023 - May 2026
Study type
Interventional
Intervention/Treatment
Drug : VX-264
Estimated enrollment
17
Interested in this trial?
About clinical trials
Volunteers who participate in clinical trials help make new medicines a reality. Clinical trials are carefully designed research studies in humans that evaluate the safety and efficacy of an investigational medicine.
If you’re interested in participating in a Vertex clinical trial, we encourage you to speak with your health care provider first about what’s involved and your eligibility.
Location
Search for the closest clinical trial from your location
-
Recruiting1UHealth Diabetes Research InstituteMiami Florida 33136 United States
-
Recruiting1University of ChicagoChicago Illinois 60637 United States
-
Recruiting1Massachusetts General HospitalBoston Massachusetts 02114 United States
-
Recruiting1Hospital of the University of PennsylvaniaPhiladelphia Pennsylvania 19104 United States
-
Recruiting1University of Pittsburgh Medical Center MontefiorePittsburgh Pennsylvania 15213 United States